Compare MEOH & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEOH | LIVN |
|---|---|---|
| Founded | 1968 | 1987 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 1995 | 2015 |
| Metric | MEOH | LIVN |
|---|---|---|
| Price | $53.32 | $81.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $58.33 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 984.3K | 545.6K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | $25.43 | $9.79 |
| Revenue Next Year | N/A | $6.63 |
| P/E Ratio | ★ $16.44 | $201.45 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.00 | $41.02 |
| 52 Week High | $66.75 | $85.27 |
| Indicator | MEOH | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 56.89 |
| Support Level | $52.40 | $61.63 |
| Resistance Level | $59.09 | $85.27 |
| Average True Range (ATR) | 1.70 | 2.26 |
| MACD | 0.63 | -0.36 |
| Stochastic Oscillator | 52.59 | 75.12 |
Methanex Corp operates as a producer and supplier of methanol to various international markets in North America, Asia Pacific, Europe and South America. The company's operations consist prominently of the production and sale of methanol, along with the production and sale of ammonia. Geographically, it operates in China, Europe, the United States, South America, South Korea, Other Asia, and Canada. The majority of revenue is derived from Europe.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.